The ASRC has a very strong potential for both basic and translational biomedical research. The research work is carried out in collaboration with the clinical and biological services of the Saint-Antoine-Tenon-Armand Trousseau hospitals belonging to the same hospital group. The CRSA is made up of 13 research teams certified by Inserm and Sorbonne University and an administrative team, located mainly at the Saint-Antoine and Armand Trousseau hospitals.<\/p>\n
<\/p>\n
Saint Antoine Hospital – Sorbonne University
\nKourilsky Building
\n34 rue Crozatier 75012 PARIS<\/p>\n
<\/p>\n
www.crsa.fr<\/a><\/p>\n <\/p>\n Mail:<\/strong> cm.crsa@inserm.fr<\/a><\/p>\n Telephone:<\/strong> +33(0)1.49.28.46.00<\/p>\n <\/p>\n INSERM and Sorbonne University<\/strong><\/p>\n <\/p>\n FEVE Bruno<\/strong><\/p>\n <\/p>\n <\/p>\n Our research team studies the immunological mechanisms and side effects of immunotherapy and targeted therapies in hematological malignancies.<\/p>\n https:\/\/www.crsa.fr\/equipe-mohamad-mohty.html<\/a><\/p>\n <\/p>\n Department<\/strong><\/p>\n Oncology – Hematology<\/a><\/p>\n <\/p>\n Manager \/ Team Leader<\/strong><\/p>\n Mohamad Mohty<\/p>\n The work carried out in the team addresses two fundamental aspects of hematology: the understanding of the mechanisms of development of acute myeloid leukemia (AML) and the study of hematopoiesis and erythropoiesis with a view to transfusion and cell therapy. Three groups are divided along these two axes while interacting closely.<\/p>\n https:\/\/www.crsa.fr\/equipe-mohamad-mohty.html<\/a><\/p>\n <\/p>\n Department<\/strong><\/p>\n Oncology – Hematology<\/a><\/p>\n <\/p>\n Manager \/ Team Leader<\/strong><\/p>\n Fran\u00e7ois Delhommeau<\/p>\n Transforming Growth Factor beta or TGF-B is a multifunctional cytokine that plays a key role in the biology of metazoans, from the early stages of embryogenesis to the regeneration of mature tissue. TGF-B maintains tissue homeostasis through a multitude of processes, such as regulation of pluripotency, stem cell differentiation, and suppression of the oncogenic capacity of premalignant cells. However, TGF-B may also exert pro-metastatic functions by promoting cell migration and invasion in later stages of cancer. However, the mechanisms by which TGF-B exerts this dual role during carcinogenesis remain poorly understood. In this context, our research projects aim at elucidating the interactions between key components of the TGF-B signaling pathway, in particular during tumor and metastatic progression and in cellular plasticity processes.<\/p>\n https:\/\/www.crsa.fr\/equipe-celine-prunier.html<\/a><\/p>\n <\/p>\n Department<\/strong><\/p>\n Oncology – Hematology<\/a><\/p>\n <\/p>\n Manager \/ Team Leader<\/strong><\/p>\n C\u00e9line Prunier<\/p>\n Our research focuses on the following areas:<\/p>\n https:\/\/www.crsa.fr\/equipe-michele-sabbah.html<\/a><\/p>\n <\/p>\n Department<\/strong><\/p>\n Oncology – Hematology<\/a><\/p>\n <\/p>\n Manager \/ Team Leader<\/strong><\/p>\n Mich\u00e8le Sabbah<\/p>\n The topics for our research group are focused on the study of mismatch repair (MMR)-deficient human tumors that develop through a particular molecular pathway characterized by the genetic instability of numerous microsatellite repeat sequences throughout the genome (MSI tumors). Since founded, the research interest of our lab is the analysis of the genetics of MSI tumors whatever their localization. The overall aim of our activity is to investigate important pathophysiological aspects of MSI carcinogenesis. Questions and hypothesis, on the fundamental and clinical sides, related to this particular tumor type are deduced from the analysis of causes and functional consequences of the microsatellite instability process characteristics of these tumors.<\/p>\n https:\/\/www.crsa.fr\/equipe-alex-duval.html<\/a><\/p>\n <\/p>\n Department<\/strong><\/p>\n Oncology – Hematology<\/a><\/p>\n <\/p>\n Manager \/ Team Leader<\/strong><\/p>\n Alex Duval<\/p>\n The team’s objective is to find new mechanisms, therapies and predictive tests for the progression or regression of liver diseases, whether they are rare diseases such as biliary diseases or very common diseases such as chronic viral hepatitis or non-alcoholic fatty liver disease (NAFLD). Cohort studies are being conducted to better define biliary diseases, including those caused by genetic defects in the phosphatidyl choline transporter, ABCB4. The mechanisms of ABCB4 trafficking and function, the effect of missense variants and the response of these variants to pharmacological agents, are analyzed using 3D structural modeling of the transporter, polarized cells and transgenic mice.<\/p>\n https:\/\/www.crsa.fr\/equipe-chantal-housset.html<\/a><\/p>\n <\/p>\n Department<\/strong><\/p>\n Metabolism – Inflammation<\/a><\/p>\n <\/p>\n Manager \/ Team Leader<\/strong><\/p>\n Housset Chantal<\/p>\n The main objective of our team is to decipher the mechanisms underlying gut microbiota-host interactions in physiology and in various pathologies, in particular those associated with intestinal inflammation. Our team, co-directed by Philippe Seksik and Harry Sokol, is currently working on several aspects of the pathogenesis of chronic inflammatory bowel disease (IBD), a common disease affecting up to 1% of the population.<\/p>\n https:\/\/www.crsa.fr\/equipe-philippe-seksik.html<\/a><\/p>\n <\/p>\nContact<\/h2>\n
Guardianship<\/h2>\n
Director \/ Head of structure<\/h2>\n
Research units<\/h2>\n
\nGraft versus host disease after allogeneic hematopoietic stem cell transplantation<\/h3>\n
\nHematopoietic and leukemic development: diseases and cell therapy<\/h3>\n
\nTGF-\u03b2 singularization in cellular plasticity and cancer<\/h3>\n
\nBiology and therapeutics of cancer<\/h3>\n
\n
\nMicrosatellite instability and cancer<\/h3>\n
\nFibro-inflammatory diseases of metabolic and biliary origin of the liver<\/h3>\n
\nGut microbiota and inflammation<\/h3>\n